Tag Archives: Michigan

The wonders of Zebrafish

Zebrafish may hold key to greater understanding of common diseases.

A two-inch stripy fish that spends its life in the tropical freshwater streams might not seem an obvious target for discovering more about what causes type 2 diabetes, prostate cancer and Alzheimer’s, but according to researchers at Queen Mary, University of London, UK, it could be key to revealing important mechanisms involved in the progression of these diseases.

Zebrafish are like the lab rats of the aquatic world – they develop extremely quickly and the transparent embryos can be grown outside the mother’s body, which allows scientists to observe their organs clearly, making them ideal subjects for assessing how certain substances affect our bodies. In this study, researchers were looking at the effects of zinc. An essential mineral, it is utilised by the body for cell growth, the immune system, brain function, and reproduction. Although scientists believe zinc is key to further understanding of type 2 diabetes, prostate cancer and Alzheimer’s, they’re uncertain as to what its role is.

Zebrafish

Zebrafish

Using the zebrafish the researchers were able to develop a sensor that picks up areas in the fish’s body where zinc is present, such as the pancreas, for example. If the researchers can show similar results with the same technique on larger animals and humans, it could prove an effective way to fully understand the role of zinc in disease.

A recent study from the University of Michigan, US, indicates that zinc has the potential to prevent the shut down of insulin-producing cells. The same process also hinders the production of harmful processes involved in Alzheimer’s disease. The Michigan researchers are now hoping to find out exactly how zinc interacts with the body’s other molecules to help prevent diseases such as diabetes. Perhaps the zebrafish will prove to be the key that unlocks the secret.


As this mineral can’t be produced by the body, we need to get it from food. It is possible, however, to take too much: an intake of around 11 mg for a male adult and 8 mg for women is ideal. “Protein appears to aid the absorption of zinc, and it’s found in a wide variety of protein foods,” says registered nutritionist Dr Carina Norris, author of The Food Manual. “Lean cuts of beef, venison, turkey and seafood are excellent sources. You can also get it from vegetarian food sources, such as sesame and pumpkin seeds, but phytate compounds, found mainly high-fibre plant-based foods, hinder the absorption of zinc, so it’s harder for vegetarians to take in enough of this mineral, as they generally eat more phytates.”

New cancer drug looks promising

Scientists at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells.

The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppressor function.

This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53.

Cancer cells

Cancer cells

“For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer,” said lead study author Shaomeng Wang.

Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects.

These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study researchers showed that these new drugs shrank tumors without significant side effects.


Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer.

Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.

The study was presented at the American Association for Cancer Research 102nd annual meeting.